I
IntoCare
Innovative medical solutions focused on improving patient care through precision and eco-friendliness, with a patented and energy-saving stapling platform
About IntoCare
IntoCare is a high-tech Chinese company specializing in the development, manufacturing, and commercialization of advanced surgical devices. Founded in 2015 and headquartered in Suzhou, China, IntoCare operates in one of the most innovative and economically developed regions. The company employs over 150 professionals with global expertise and experience in multinational medical device companies.
IntoCare's core product is the Intelligent Powered Stapling Platform, a cutting-edge surgical device designed to improve clinical outcomes and cost efficiency. The company is committed to evidence-based medicine, ensuring that their products provide clear and documented clinical, quality, and operational (C.Q.O.) benefits.
The company serves healthcare providers, including hospitals and surgical centers, aiming to enhance the quality of patient care through innovative solutions. IntoCare's business model revolves around the continuous development and commercialization of high-tech surgical devices, supported by strong financial backing from multiple international venture capital partnerships.
Revenue is generated through the sale of these advanced surgical devices, which are designed to offer both clinical and economic benefits to healthcare providers. By focusing on innovation and quality, IntoCare aims to establish itself as a leader in the medical device industry, improving healthcare outcomes for all stakeholders.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Suzhou Shi, China
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 39.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Surgical Equipment, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2023 | $0 | — | Qiming Venture Partners | — |
| SERIES DOther financing | May 2021 | $16M | $63M | Oriza FOFs · Qiming Venture Partners · Oriza Holdings · Yuansheng BioVenture | — |
Growth signals
Latest recorded traffic for IntoCare is 400 monthly website visits, down 59.2% over the last three months. IntoCare's team declined 3.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later3 investors entered at this stage
Oriza FOFs
Oriza Holdings
Yuansheng BioVenture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IntoCare on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IntoCare’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.